RapidAI Enhances Aneurysm Detection in Largest Real-World Study to Date SAN MATEO, Calif.--(BUSINESS WIRE)--RapidAI, a leading provider of AI-based clinical decision support and enterprise radiology solutions, has unveiled significant findings from the largest real-world study on AI for aneurysm detection. The results, presented at the 2025 American Association of Neurological Surgeons (AANS) Annual Meeting, highlight the platform's ability to improve diagnostic confidence and consistency, especially in identifying subtle or difficult-to-see intracranial aneurysms. The retrospective, single-center study analyzed 11,694 consecutive computed tomography angiography (CTA) scans. Using RapidAI's clinically validated platform, Rapid Aneurysm, researchers found that nearly 23% more aneurysms were identified compared to the original radiology reports. These additional detections, with a median size of 3.9 mm, were often significant enough to require intervention. "Detecting aneurysms can be extremely challenging, particularly in a busy clinical environment where they might be subtly positioned," noted Dr. Reza Dashti, an associate professor of neurosurgery and the lead study investigator. "Our study underscores the potential of AI to augment clinical expertise and significantly enhance diagnostic accuracy in real-world settings." The study further demonstrated RapidAI's exceptional performance in detecting aneurysms that were 3 mm or larger. In this category, the platform achieved a sensitivity of 92.5% and a specificity of 96.4%, indicating a high degree of reliability and precision. Dr. David Stoffel, chief business officer at RapidAI, emphasized the practical implications of these findings. "Given the growing pressures on radiology teams, this study highlights the potential of AI to provide meaningful support, improving both diagnostic capabilities and clinical workflows," he stated. "Enhanced accuracy not only leads to better patient outcomes but also helps reduce the costs associated with missed or delayed aneurysm diagnoses." RapidAI's aneurysm detection platform integrates advanced 3D visualization, growth tracking, and automated measurements, offering clinicians a comprehensive and detailed view of their patients' conditions. This comprehensive approach boosts confidence in clinical decisions and streamlines the diagnostic process. With this study, RapidAI continues to set new standards in AI-driven medical imaging and coordinated care. The company's platform is trusted by thousands of hospitals in over 100 countries, providing the most validated clinical AI in the market. Beyond just the algorithm, RapidAI focuses on fostering collaboration among care teams and enhancing workflow efficiency to ensure timely and effective treatment. In summary, the study presented at AANS 2025 showcases the transformative impact of RapidAI's technology on aneurysm detection. By augmenting the capabilities of healthcare professionals, it not only improves patient outcomes but also addresses the challenges faced by radiology teams in busy medical settings. RapidAI remains committed to advancing the field of neurovascular care through innovative AI solutions.